RiteMED Cefuroxime Adverse Reactions

Tablet: The following adverse events have been reported with the use of cefuroxime, although in many instances the casual relationship to the drug has not been established: Dermatologic/Hypersensitivity Reactions: Rash (e.g., morbilliform), pruritus/itch, erythema, urticaria/hives, drug fever, chills, edema, facial edema, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthemic necrolysis), serum sickness-like reactions, shock, hypotension, vasodilatation, shortness of breath, bronchospasm, angioedema, anaphylaxis, candida overgrowth.
Gastrointestinal (GI): Nausea, vomiting, diarrhea, or loose stools, gagging, abdominal/epigastric pain, abdominal cramps, dyspepsia, flatulence, heartburn, indigestion, GI bleeding, tenesmus, GI infection, decreased salivation, ptyalism, glossitis/swollen tongue, taste alteration, mouth ulcers/candidiasis, decreased appetite/anorexia, thirst, Clostridium difficile-associated diarrhea and colitis (antibiotic-associated pseudomembranous colitis).
Hematologic: Decreased hematocrit and hemoglobin concentrations, transient eosinophilia and neutropenia, pancytopenia, thrombocytopenia, leukopenia, lymphocytopenia, agranulocytosis, leukocytosis, lymphocytosis, monocytosis, thrombocytosis, basophilia, anemia, aplastic anemia, hemolytic anemia, epistaxis or hemorrhage, increased erythrocyte sedimentation rate, prolonged prothrombin time (PT), prolonged activated partial thromboplastin time (APTT), and/or hypoprothrombinemia (with or without bleeding).
Nervous System: Headache, dizziness, vertigo, malaise, fatigue, drowsiness, somnolence or sleepiness, weakness, insomnia, nightmares, irritable behavior, seizures, myoclonic jerks, generalized hyperexcitability, hyperactivity, nervousness or anxiety, agitation, confusion, hallucinations, alteration in color perception, hot flushes, hypertonia.
Musculoskeletal: Muscle spasm of the neck, muscle cramps of stiffness, arthralgia/joint pain or swelling.
Genitounitary: Acute renal failure and interstitial nephritis, transient increases in blood urea nitrogen (BUN) and serum creatinine concentrations; decreased creatinine clearance; renal dysfunction, toxic nephropathy, bilateral renal cortical necrosis, kidney pain, urinary tract infection, urethral pain or bleeding, dysuria, vaginitis, vaginal candidiasis, vulvovaginal pruritus, vaginal discharge or irritation, menstrual irregularities.
Hepatic: Hepatic impairment including hepatitis and cholestasis, jaundice; transient increases in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transferase, alkaline phosphatase, lactate dehydrogense (LDH), and bilirubin concentrations; decreased serum albumin and/or total protein.
Respiratory: Pleural effusion, pulmonary infiltrate, dyspnea or respiratory distress, upper respiratory infection, rhinitis, sinusitis, cough.
Cardiovascular: Chest pain or tightness, tachycardia.
Other Adverse Effects: Jarisch-Herxheimer reaction, mild to severe hearing loss, increased or decreased serum glucose concentration, lockjaw-type reaction, viral illness.
Injection: The most common adverse effects have been local reactions following IV administration. Gastrointestinal disturbances, including diarrhea, nausea, and vomiting have occurred in some patients. There have been rare reports of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Mild to moderate hearing loss have been reported in some children given cefuroxime for the treatment of meningitis.